GPT and Hand-foot syndrome: A meta-analysis by Yu et al. found that patients treated with sorafenib experienced a higher incidence of hand-foot syndrome, hypocalcemia, rash, and elevated liver enzymes (ALT and AST) compared to those on lenvatinib [42].